Novocure's revenue has re-accelerated to $193.4M in 3Q26, up 15.7% year over year, while gross margin has held near 77.0%, suggesting the disposable Tumor Treating Fields platform retains healthy unit economics.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.09+61.7% vs -$0.23 | $193M+6.1% vs $182M |
Q3 2026 Jul 23, 2026 | -$0.13+60.8% vs -$0.33 | $184M+6.5% vs $172M |
Q2 2026 Apr 30, 2026 | -$0.62-21.0% vs -$0.51 | $174M+3.7% vs $168M |
Q1 2026 Feb 26, 2026 | -$0.22+46.3% vs -$0.41 | $174M-0.0% vs $174M |
NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient counts to a record level. The company also raised its full-year revenue and adjusted EBITDA outlook while acknowledging commercial headwinds for its newer Optune Pax therapy in the United States.
NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou.
Ambu A/S (OTCMKTS:AMBBY - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Risk and Volatility Ambu A/S has a beta of
Benchmark NVCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Novocure Ltd (NVCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $676.04 | $53.33B | 45.20 | 10.42% | 25.36% | 71.18% | — |
Novocure Ltd (NVCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Novocure Ltd (NVCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 1, 2026·SEC
Jul 23, 2026·SEC
Get notified when NVCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novocure Ltd (NVCR) stock FAQ — growth, dividends, profitability & financials explained
Novocure Ltd (NVCR) reported $725.4M in revenue over the trailing twelve months. Revenue was $655.4M in fiscal year 2025. That is 6226% more than the $10.4M of fiscal year 2013.
Novocure Ltd (NVCR) grew revenue by 12.9% over the trailing twelve months, compared with the twelve months before.
No. Novocure Ltd (NVCR) reported a net loss of $121.7M over the trailing twelve months.
Novocure Ltd (NVCR) had a return on equity (ROE) of -35.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Novocure Ltd (NVCR) had negative free cash flow of $20.3M over the trailing twelve months.
